Tyrosine kinase inhibitors (TKIs), mTOR inhibitors, and VEGF inhibitors are molecularly targeted drugs frequently used to treat RCC and have been demonstrated to improve the overall prognosis of patients with unresectable or metastatic RCC. This evidence concerns the gene VEGFA and renal cell adenocarcinoma.